Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents

Pharmacotherapy

Volumn 29, Issue 8, 2009, Pages 975-987

  Schneiderhan, Mark E ^a   Batscha, Catherine L ^b   Rosen, Cherise ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antipsychotic treatment; Mental illness; Metabolic risk screening; Metabolic syndrome; Point of care testing

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

ABDOMINAL OBESITY; ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BIPOLAR DISORDER; BODY MASS; CIGARETTE SMOKING; DIABETES MELLITUS; FEMALE; HEALTH PROGRAM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL INFORMATION; METABOLIC DISORDER; NURSE; OUTPATIENT; PATIENT CODING; PHARMACIST; POINT OF CARE TESTING; RISK ASSESSMENT; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; VITAL SIGN; WAIST CIRCUMFERENCE;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; COHORT STUDIES; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MENTAL DISORDERS; METABOLIC SYNDROME X; METABOLISM; POINT-OF-CARE SYSTEMS; RETROSPECTIVE STUDIES;

EID: 68149164584     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.8.975     Document Type: Article

References (27)

1. Meyer JM, Davis VG, McEvoy JP, et al. Impact of antipsychotic treatment on nonfasting triglycerides in CATIE schizophrenia trial phase 1. Schizophr Res 2008;103:104-109
2. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32.
3. Dickerson FB, Brown CH, Daumit Dl, et al. Health status of individuals with serious mental illness. Schizophr Bull 2006;32:584-589 (Pubitemid 43992332)
4. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-1121 (Pubitemid 41773510)
5. Goldberg RW, Cooke B, Hackman A. Mental health provider's involvement in diabetes management. Psychiatr Serv 2007;58:1501-1502 (Pubitemid 350207282)
6. Goldberg RW, Kreyenbuhl JA, Medoff DR, et al. Quality of diabetes care among adults with serious mental illness. Psychiatr Serv 2007;58:536-543 (Pubitemid 46640646)
7. Carney CP, Jones LE. The influence of type and severity of mental illness on receipt of screening mammography. J Gen Intern Med 2006;21:1097-1104
8. Miller E, Lasser KE, Becker AE. Breast and cervical cancer screening for women with mental illness: patient and provider perspectives on improving linkages between primary care and mental health. Arch Womens Ment Health 2007;10:189-197 (Pubitemid 47493629)
9. Bauer MS, Williford WO, McBride K, Shea NM. Perceived barriers to health care access in a treated population. Int J Psychiatry Med 2005;35:13-26. (Pubitemid 41056525)
10. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
11. McCarron RM, Keenan CR. The metabolic syndrome. In: Bermudes RA, Keck PE, McElroy SL, eds. Managing metabolic abnormalities in the psychiatrically ill. Washington, DC: American Psychiatric Publishing, Inc., 2007:25-52.
12. Mackin P, Bishop DR, Watkinson H. A prospective study of monitoring practices for metabolic disease in antipsychotictreated community psychiatric patients [online exclusive article]. BMC Psychiatry 2007;7:28. Available from http://www.biomedcentral.com/1471-244X/7/28. (Pubitemid 47055085)
13. Haupt DW, Rosenblatt LC, Kim E, et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009;166:345-353
14. Motsinger C, Slack M, Weaver M, Reed M. Physician patterns of metabolic screening for patients taking atypical antipsychotics: a retrospective database study. Prim Care Companion J Clin Psychiatry 2006;8:220-223 (Pubitemid 44371560)
15. Jennex A, Gardner DM. Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study. Can J Psychiatry 2008;53:34-42. (Pubitemid 351235839)
16. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006;15:492-501. (Pubitemid 44166337)
17. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1-16.
18. Van Winkel R, De Hert M, Van Eych D, et al. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J Clin Psychiatry 2006;67:1493-1500 (Pubitemid 44787430)
19. Puntmann I, Wosniok W, Haeckel R. Comparison of several point of care testing (POCT) glucometers with an established laboratory procedure for the diagnosis of type 2 diabetes using the discordance rate: a new statistical approach. Clin Chem Lab Med 2003;41:809-820 (Pubitemid 36840817)
20. Savoca R, Jaworek B, Huber AR. New "plasma referenced" POCT glucose monitoring systems: are they suitable for glucose monitoring and diagnosis of diabetes? Clin Chim Acta 2006;372:199-201.
21. Ghys T, Goedhuys W, Spincemaille K, Gorus F, Gerlo E. Plasma-equivalent glucose at the point of care: evaluation of Roche Accu-Chek Inform and Abbott Precision PCx glucose meters. Clin Chim Acta 2007;386:63-68 (Pubitemid 47417964)
22. Glazer WM. Point-of-care tests in behavioral health: glucose monitoring and a new lithium test can provide instant results to patients and clinicians. Behav Healthc 2006;26:37-39
23. Shephard MD, Mazzachi BC, Shephard AK, McLaughlin KJ, Denner B, Barnes G. The impact of point of care testing on diabetes services along Victoria's Mallee Track: results of a community-based diabetes risk assessment and management program [online exclusive article]. Rural Remote Health 2005;5:371. Available from http://rrh.org.au/articles/defaultnew.asp?issueNo=5x.
24. Martin DD, Shephard MD, Freeman H, et al. Point of care testing of HBA1c and blood glucose in a remote Aboriginal Australian community. Med J Aust 2005:182:524-527 (Pubitemid 40744413)
25. Shephard MD. Cultural and clinical effectiveness of the QAAMS point of care testing model for diabetes management in Australian Aboriginal medical services. Clin Biochem Rev 2006;27:161-170
26. Marley JV, Davis S, Coleman K, et al. Point of care testing of capillary glucose in the exclusion and diagnosis of diabetes in remote Australia. Med J Aust 2007;186:500-503 (Pubitemid 46895071)
27. Shemesh T, Rowley KG, Shephard M, Piers LS, O'Dea K. Agreement between laboratory results and on-site pathology testing using Bayer DCA2000+ and Cholestech LDX point of care methods in remote Australian Aboriginal communities. Clin Chim Acta 2006;367:69-76.